MA34388B1 - Compositions et procédés pour moduler la voie de signalisation wnt - Google Patents
Compositions et procédés pour moduler la voie de signalisation wntInfo
- Publication number
- MA34388B1 MA34388B1 MA35576A MA35576A MA34388B1 MA 34388 B1 MA34388 B1 MA 34388B1 MA 35576 A MA35576 A MA 35576A MA 35576 A MA35576 A MA 35576A MA 34388 B1 MA34388 B1 MA 34388B1
- Authority
- MA
- Morocco
- Prior art keywords
- modulating
- compositions
- methods
- wnt signaling
- signaling path
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000011664 signaling Effects 0.000 title 1
- 230000004156 Wnt signaling pathway Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35956910P | 2010-06-29 | 2010-06-29 | |
| PCT/US2011/042215 WO2012003189A1 (en) | 2010-06-29 | 2011-06-28 | Compositions and methods for modulating the wnt signaling pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34388B1 true MA34388B1 (fr) | 2013-07-03 |
Family
ID=44514972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35576A MA34388B1 (fr) | 2010-06-29 | 2011-06-28 | Compositions et procédés pour moduler la voie de signalisation wnt |
Country Status (27)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| US7982013B2 (en) | 2008-09-26 | 2011-07-19 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| AU2011235904B2 (en) | 2010-04-01 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| TWI567061B (zh) * | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| RU2486859C1 (ru) * | 2012-02-02 | 2013-07-10 | Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации | Способ оценки эффективности комбинированного органосохраняющего лечения первичной начальной ретинобластомы у детей |
| BR112014031263B1 (pt) | 2012-06-15 | 2022-03-29 | Curegenix Inc | Composto, composição farmacêutica, método de inibição da secreção wnt, método de inibição da sinalização wnt e uso de um composto |
| JP2015536933A (ja) * | 2012-10-23 | 2015-12-24 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法 |
| AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| ES2684360T3 (es) * | 2013-11-01 | 2018-10-02 | Novartis Ag | Aminoheteroaril benzamidas como inhibidores de quinasa |
| AU2015329784C1 (en) * | 2014-10-08 | 2020-10-15 | Redx Pharma Plc | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signalling pathway |
| PT3204381T (pt) * | 2014-10-08 | 2022-07-18 | Redx Pharma Plc | Derivados de n-piridinil acetamida como inibidores da via de sinalização wnt |
| CN104557862B (zh) * | 2014-12-15 | 2017-05-17 | 苏州云轩医药科技有限公司 | 具有Wnt信号通路抑制活性的杂环化合物 |
| EA201791737A1 (ru) | 2015-02-03 | 2018-03-30 | КАДМОН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Стабильные составы триентина |
| WO2016168524A1 (en) * | 2015-04-15 | 2016-10-20 | University Of Utah Research Foundation | Substituted n-([1,1'-biphenyl]-3-yl)-[1,1'-biphenyl]-3-carboxamide analogs as inhibitors for beta-catenin/b-cell lymphoma 9 interactions |
| CA2985813A1 (en) * | 2015-05-26 | 2016-12-01 | Curegenix Corporation | Tumor biomarkers and use thereof |
| CN107759584B (zh) * | 2016-08-16 | 2021-06-01 | 苏州云轩医药科技有限公司 | 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用 |
| CN107056754B (zh) * | 2015-12-07 | 2020-12-04 | 苏州信诺维医药科技有限公司 | 内嵌脲类结构的wnt通路抑制剂 |
| KR102214225B1 (ko) * | 2015-12-07 | 2021-02-10 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | 5원 헤테로시클릭 아미드계 wnt 경로 억제제 |
| US11542254B2 (en) | 2016-03-25 | 2023-01-03 | Universisity Of Utah Research Foundation | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors |
| US10793544B2 (en) * | 2016-09-01 | 2020-10-06 | The Board Of Regents Of The University Of Texas System | Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors |
| WO2019106156A1 (en) | 2017-11-30 | 2019-06-06 | Step Pharma S.A.S. | Compounds |
| EP3717465A1 (en) * | 2017-11-30 | 2020-10-07 | Step Pharma S.A.S. | Compounds |
| WO2019124603A1 (ko) * | 2017-12-22 | 2019-06-27 | 경상대학교병원 | Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물 |
| PE20251292A1 (es) | 2018-03-08 | 2025-05-14 | Incyte Corp | Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| CN111662228B (zh) * | 2019-03-07 | 2023-07-28 | 中国医学科学院药物研究所 | 吡啶酮酰联芳基胺类化合物及其用途 |
| US12466810B2 (en) | 2019-06-04 | 2025-11-11 | Step Pharma S.A.S. | N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases |
| CA3239071A1 (en) | 2021-11-25 | 2023-06-01 | Fanglong Yang | Chimeric compound for targeted degradation of androgen receptor protein, preparation method therefor, and medical use thereof |
| US20230399299A1 (en) * | 2022-06-14 | 2023-12-14 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| FR2847253B1 (fr) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| US20080275062A1 (en) * | 2004-01-30 | 2008-11-06 | David Harold Drewry | Chemical Compounds |
| CA2637620A1 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| KR20090060334A (ko) * | 2006-09-08 | 2009-06-11 | 제넨테크, 인크. | Ｗｎｔ 길항제 및 ｗｎｔ-매개 장애의 진단 및 치료에서의 이의 용도 |
| EP2215049B1 (en) | 2007-10-31 | 2019-06-12 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| AU2008335709A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
| AU2009225869B2 (en) * | 2008-03-18 | 2014-01-23 | Merck Sharp & Dohme Llc | Substituted 4-hydroxypyrimidine-5-carboxamides |
| EP2303862B1 (en) * | 2008-05-27 | 2016-08-24 | The Board of Regents of The University of Texas System | Wnt protein signalling inhibitors |
| US8384140B2 (en) | 2008-07-29 | 2013-02-26 | International Business Machines Corporation | Structure for dual contact trench capacitor and structure thereof |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
-
2011
- 2011-06-27 UY UY0001033469A patent/UY33469A/es not_active Application Discontinuation
- 2011-06-28 PH PH1/2012/502571A patent/PH12012502571A1/en unknown
- 2011-06-28 EA EA201390032A patent/EA201390032A1/ru unknown
- 2011-06-28 WO PCT/US2011/042215 patent/WO2012003189A1/en not_active Ceased
- 2011-06-28 JP JP2013518581A patent/JP5778270B2/ja active Active
- 2011-06-28 ES ES11733945.7T patent/ES2536216T3/es active Active
- 2011-06-28 SG SG2012095980A patent/SG186473A1/en unknown
- 2011-06-28 KR KR1020137002280A patent/KR20130131290A/ko not_active Withdrawn
- 2011-06-28 MA MA35576A patent/MA34388B1/fr unknown
- 2011-06-28 CN CN201180032354.9A patent/CN102958917B/zh active Active
- 2011-06-28 CA CA2803879A patent/CA2803879A1/en not_active Abandoned
- 2011-06-28 BR BR112012033350A patent/BR112012033350A2/pt not_active IP Right Cessation
- 2011-06-28 US US13/701,982 patent/US9181235B2/en active Active
- 2011-06-28 AU AU2011271479A patent/AU2011271479B2/en not_active Expired - Fee Related
- 2011-06-28 PE PE2012002648A patent/PE20130311A1/es not_active Application Discontinuation
- 2011-06-28 EP EP11733945.7A patent/EP2588453B1/en active Active
- 2011-06-28 MX MX2012015092A patent/MX2012015092A/es not_active Application Discontinuation
- 2011-06-29 AR ARP110102283A patent/AR082029A1/es not_active Application Discontinuation
- 2011-06-29 TW TW100122939A patent/TW201206921A/zh unknown
-
2012
- 2012-12-05 TN TNP2012000575A patent/TN2012000575A1/en unknown
- 2012-12-20 CU CU2012000174A patent/CU20120174A7/es unknown
- 2012-12-20 NI NI201200190A patent/NI201200190A/es unknown
- 2012-12-20 CL CL2012003604A patent/CL2012003604A1/es unknown
- 2012-12-27 CO CO12234891A patent/CO6650353A2/es unknown
- 2012-12-27 DO DO2012000329A patent/DOP2012000329A/es unknown
-
2013
- 2013-01-14 ZA ZA2013/00319A patent/ZA201300319B/en unknown
- 2013-01-29 EC ECSP13012410 patent/ECSP13012410A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6650353A2 (es) | 2013-04-15 |
| AU2011271479A1 (en) | 2013-02-07 |
| CN102958917B (zh) | 2014-10-08 |
| MX2012015092A (es) | 2013-03-05 |
| KR20130131290A (ko) | 2013-12-03 |
| DOP2012000329A (es) | 2013-07-15 |
| TW201206921A (en) | 2012-02-16 |
| US9181235B2 (en) | 2015-11-10 |
| CA2803879A1 (en) | 2012-01-05 |
| CN102958917A (zh) | 2013-03-06 |
| AR082029A1 (es) | 2012-11-07 |
| SG186473A1 (en) | 2013-02-28 |
| WO2012003189A1 (en) | 2012-01-05 |
| JP2013533879A (ja) | 2013-08-29 |
| BR112012033350A2 (pt) | 2016-11-29 |
| PE20130311A1 (es) | 2013-03-23 |
| ECSP13012410A (es) | 2013-03-28 |
| JP5778270B2 (ja) | 2015-09-16 |
| US20130079328A1 (en) | 2013-03-28 |
| UY33469A (es) | 2012-01-31 |
| CU20120174A7 (es) | 2013-04-19 |
| ES2536216T3 (es) | 2015-05-21 |
| NI201200190A (es) | 2013-04-15 |
| EP2588453B1 (en) | 2015-04-01 |
| TN2012000575A1 (en) | 2014-04-01 |
| AU2011271479B2 (en) | 2014-08-14 |
| CL2012003604A1 (es) | 2013-03-22 |
| EA201390032A1 (ru) | 2013-06-28 |
| PH12012502571A1 (en) | 2020-10-19 |
| ZA201300319B (en) | 2014-10-29 |
| EP2588453A1 (en) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34388B1 (fr) | Compositions et procédés pour moduler la voie de signalisation wnt | |
| CO6450669A2 (es) | Composiciones y metodos para modular la senda de señalizacion de wnt | |
| EA200971140A1 (ru) | Триарильные соединения и композиции, их содержащие | |
| MA33275B1 (fr) | Inhibiteurs de la replication du virus de l'immunodeficience humaine | |
| EP2195582A4 (en) | SCENT DELIVERY SYSTEM | |
| MA34677B1 (fr) | Compositions pesticides et procedes apprentes | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| EA201170396A1 (ru) | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции | |
| MA31906B1 (fr) | Inhibiteurs de la replication du virus de limmunodeficience humaine | |
| MA31907B1 (fr) | Nouveaux herbicides | |
| EA201100875A1 (ru) | Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов | |
| UY31274A1 (es) | Composiciones de recubrimiento electrodepositable que contiene una guanidina ciclica | |
| ECSP088854A (es) | Moduladores bencimidazolicos de vr1 | |
| MX2010001484A (es) | Derivados de pirrolidin-2-ona como moduladores del receptor de androgeno. | |
| NO20082413L (no) | Mikrobiocidal sammensetning | |
| EA201000814A1 (ru) | 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств | |
| CY1110943T1 (el) | Νεα μεθοδος διαχωρισμου των εναντιομερων του (3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριεν-7-υλ) νιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης | |
| UA106880C2 (uk) | Нові гербіциди | |
| AR047526A1 (es) | Halogenoalquilcarboxamidas | |
| CO6251376A2 (es) | Triazolilpiridina cetonas herbicidas | |
| ATE459620T1 (de) | Benzimidazolthiophenverbindungen als plk- modulatoren | |
| HN2011000745A (es) | Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida | |
| MA32834B1 (fr) | 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines | |
| ATE538149T1 (de) | Diblockcopolymer mit aus styrol abgeleiteten einheiten und aus acrylsäure abgeleiteten einheiten | |
| ATE533477T1 (de) | Pharmazeutische zusammensetzungen enthaltend irbesartan |